News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Encysive Pharmaceuticals (ENCY) Launches THELIN (sitaxentan sodium) in Belgium and Luxembourg


1/14/2008 11:29:14 AM

HOUSTON, Jan. 14, 2008 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) today announced the commercial availability of THELIN(r)(1) (sitaxentan sodium(2)) 100 mg tablets in Belgium and Luxembourg for the treatment of pulmonary arterial hypertension (PAH). Encysive received European Union (EU) marketing authorization for THELIN from the European Commission in August 2006. THELIN is the first selective endothelin A receptor antagonist, and the first once-daily oral treatment commercially available for PAH patients in the EU.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES